アカバ　トモヒロ   AKABA Tomohiro   赤羽　朋博    所属   医学部 医学科（東京女子医科大学病院）    職種   助教
論文種別	症例報告
言語種別	英語
査読の有無	査読なし
表題	The relationship between severe acute respiratory syndrome coronavirus 2 omicron variant epidemic and acute myocardial infarction: A self-controlled case series study.
掲載誌名	正式名：Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 略　 称：J Infect Chemother ISSNコード：14377780/1341321X
掲載区分	国内
巻・号・頁	31(4),pp.102666
著者・共著者	Jun Suzuki, Tomoki Mizuno, Shota Takahashi, Haruka Imai, Hideya Itagaki, Tomohiro Akaba, Makiko Yoshida, Shiro Endo
発行年月	2025/04
概要	BACKGROUND:The coronavirus disease 2019 (COVID-19) pandemic has led to various complications, including cardiovascular events. Despite the widespread impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant in 2022, no studies have evaluated the relationship between the Omicron variant epidemic and acute myocardial infarction (AMI).METHODS:We utilized a Japanese claims database to identify patients diagnosed with COVID-19 between January 1, 2022, and December 31, 2022. We also identified patients who developed AMI within 90 days before and after their COVID-19 diagnosis. A self-controlled case series (SCCS) analysis evaluated the incidence rate ratio (IRR) for AMI.RESULTS:Of the 360,589 patients with COVID-19, 759 were diagnosed with AMI. Excluding the day of exposure, the SCCS analysis showed an IRR for AMI of 6.65 (95 % confidence interval [CI]: 4.66-9.48, P < 0.001) for the 1st week, 1.90 (95 % CI: 1.05-3.50, P = 0.03) for the 2 nd week, and 0.95 (95 % CI: 0.52-1.72, P = 0.87) for the 3rd and 4th weeks following COVID-19. Including the day of exposure, the IRR was 77.4 (95 % CI: 63.2-94.9, P < 0.001) for the 1st week, 1.90 (95 % CI: 1.05-3.50, P = 0.03) for the 2 nd week, and 0.95 (95 % CI: 0.52-1.72, P = 0.87) for the 3rd and 4th weeks following COVID-19.CONCLUSIONS:This study showed that the SARS-CoV-2 Omicron variant epidemic increased AMI incidence. These findings highlight AMI as a COVID-19 characteristic, emphasize the importance of SARS-CoV-2 vaccination, and underline the need for continued vigilance, even with variant changes.
DOI	10.1016/j.jiac.2025.102666
PMID	40021005